These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32062308)

  • 1. Venous thromboembolism in multiple sclerosis: a report of two cases with pulmonary embolism on dimethyl fumarate and available data from adverse event reporting systems. Time to include disease modifying drugs in the equation?
    Papathanasiou A; Abdel-Fahim R; Gilmore C; Evangelou N
    Clin Neurol Neurosurg; 2020 May; 192():105726. PubMed ID: 32062308
    [No Abstract]   [Full Text] [Related]  

  • 2. Comorbidity influences therapeutic approach in multiple sclerosis.
    Capone F; Ferraro E; Florio L; Marcoccia A; Di Lazzaro V; Di Battista G
    Clin Neurol Neurosurg; 2017 Apr; 155():14-16. PubMed ID: 28212926
    [No Abstract]   [Full Text] [Related]  

  • 3. [Dimethyl fumarate (tecfidera) is the first line treatment choice in patients with remitting multiple sclerosis].
    Shmidt TE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):140-145. PubMed ID: 29265100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective.
    Chevalier J; Chamoux C; Hammès F; Chicoye A
    PLoS One; 2016; 11(3):e0150703. PubMed ID: 26987055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dimethylfumarate in the treatment of relapsing-remitting multiple sclerosis].
    Popova EV; Boyko AN; Orlova EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10 Pt 2):68-72. PubMed ID: 28139614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NICE approval of dimethyl fumarate could benefit thousands living with relapsing-remitting multiple sclerosis.
    Boulicault D; Duddy M
    Neurodegener Dis Manag; 2015; 5(1):7-10. PubMed ID: 25711449
    [No Abstract]   [Full Text] [Related]  

  • 7. Dimethyl Fumarate: A Review in Relapsing-Remitting MS.
    Blair HA
    Drugs; 2019 Dec; 79(18):1965-1976. PubMed ID: 31784875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
    Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis.
    Losavio FA; Lucchini M; De Fino C; Mirabella M; Nociti V
    Mult Scler Relat Disord; 2016 May; 7():68-9. PubMed ID: 27237761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fulminant rebound of relapsing-remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report.
    Harmel P; Schlunk F; Harms L
    Mult Scler; 2018 Jul; 24(8):1131-1133. PubMed ID: 29708444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis.
    Yadav SK; Soin D; Ito K; Dhib-Jalbut S
    J Mol Med (Berl); 2019 Apr; 97(4):463-472. PubMed ID: 30820593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical guidelines for the use of dimethyl fumarate in relapsing-remitting multiple sclerosis].
    Alifirova VM; Boiko AN; Vlasov YV; Davydovskaya MV; Zakharova MN; Malkova NA; Popova EV; Sivertseva SA; Spirin NN; Khachanova NV; Shmidt ТЕ
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(1):97-102. PubMed ID: 28252608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dimethyl Fumarate: A Review in Relapsing-Remitting MS.
    Deeks ED
    Drugs; 2016 Feb; 76(2):243-54. PubMed ID: 26689201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.
    Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
    J Neurol; 2021 Mar; 268(3):941-949. PubMed ID: 32974794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
    Kalincik T; Kubala Havrdova E; Horakova D; Izquierdo G; Prat A; Girard M; Duquette P; Grammond P; Onofrj M; Lugaresi A; Ozakbas S; Kappos L; Kuhle J; Terzi M; Lechner-Scott J; Boz C; Grand'Maison F; Prevost J; Sola P; Ferraro D; Granella F; Trojano M; Bergamaschi R; Pucci E; Turkoglu R; McCombe PA; Pesch VV; Van Wijmeersch B; Solaro C; Ramo-Tello C; Slee M; Alroughani R; Yamout B; Shaygannejad V; Spitaleri D; Sánchez-Menoyo JL; Ampapa R; Hodgkinson S; Karabudak R; Butler E; Vucic S; Jokubaitis V; Spelman T; Butzkueven H
    J Neurol Neurosurg Psychiatry; 2019 Apr; 90(4):458-468. PubMed ID: 30636699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.
    Palte MJ; Wehr A; Tawa M; Perkin K; Leigh-Pemberton R; Hanna J; Miller C; Penner N
    Adv Ther; 2019 Nov; 36(11):3154-3165. PubMed ID: 31538304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017.
    Vermersch P; Suchet L; Colamarino R; Laurendeau C; Detournay B
    Mult Scler Relat Disord; 2020 Nov; 46():102521. PubMed ID: 32977077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
    Guarnera C; Bramanti P; Mazzon E
    Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada.
    Dorman E; Kansal AR; Sarda S
    J Med Econ; 2015; 18(12):1085-91. PubMed ID: 26390149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
    Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
    J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.